While Ligand Pharmaceuticals, Inc has overperformed by 0.24%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LGND rose by 48.73%, with highs and lows ranging from $129.90 to $67.53, whereas the simple moving average jumped by 13.30% in the last 200 days.
On October 03, 2024, Oppenheimer started tracking Ligand Pharmaceuticals, Inc (NASDAQ: LGND) recommending Outperform. A report published by RBC Capital Mkts on July 30, 2024, Initiated its previous ‘Outperform’ rating for LGND. Stephens also rated LGND shares as ‘Overweight’, setting a target price of $200 on the company’s shares in an initiating report dated April 14, 2021. H.C. Wainwright Reiterated the rating as Buy on February 04, 2021, but set its price target from $229 to $310. Barclays initiated its ‘Overweight’ rating for LGND, as published in its report on October 06, 2020. Guggenheim also rated the stock as ‘Neutral’.
Analysis of Ligand Pharmaceuticals, Inc (LGND)
Further, the quarter-over-quarter increase in sales is 57.64%, showing a positive trend in the upcoming months.
One of the most important indicators of Ligand Pharmaceuticals, Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of 6.00% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 11.70, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and LGND is recording 121.76K average volume. On a monthly basis, the volatility of the stock is set at 4.64%, whereas on a weekly basis, it is put at 4.02%, with a gain of 3.20% over the past seven days. Furthermore, long-term investors anticipate a median target price of $142.38, showing growth from the present price of $110.58, which can serve as yet another indication of whether LGND is worth investing in or should be passed over.
How Do You Analyze Ligand Pharmaceuticals, Inc Shares?
The Biotechnology market is dominated by Ligand Pharmaceuticals, Inc (LGND) based in the USA. When comparing Ligand Pharmaceuticals, Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 44.00, there is a growth in quarterly earnings of 34.12%.
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 2.22%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 97.02% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
LGND shares are owned by institutional investors to the tune of 97.02% at present.
